TB Elimination Alliance Impact Report: 2019-2024
This report summarizes the TB Elimination Alliance's (TEA) activities and outcomes from 2019 to 2024.
This report summarizes the TB Elimination Alliance's (TEA) activities and outcomes from 2019 to 2024.
This journal examines the treatment of chlamydia and gonorrhea in primary care settings and its impact on patients' subsequent health care utilization.
This journal presents a spatial–temporal modeling study examining how city-level sociodemographic and health-related factors influenced the prevalence of antimicrobial-resistant gonorrhea in the U.S. from 2000 to 2019.
This journal examines the role of circular RNAs (circRNAs) in HIV-1 replication, highlighting the discovery that backsplicing of the HIV-1 transcript produces multiple circRNAs that enhance viral replication.
This journal discusses the development of a handheld platform designed for the detection of HIV, utilizing paper-based sample preparation and real-time isothermal amplification.
This journal presents findings from a pilot randomized clinical trial evaluating two brief interventions aimed at increasing HIV pre-exposure prophylaxis (PrEP) uptake among rural people who inject drugs (PWID) attending syringe services programs (SSPs) in Kentucky.
This journal discusses the integration of hepatitis C management into primary care as a key strategy for eliminating the disease. It examines barriers to care, the role of direct-acting antivirals, and the importance of screening and treatment within primary care settings.
This journal examines the clinical course of autoimmune hepatitis (AIH) in Hispanic and African American patients at a South Bronx hospital. The findings contribute to a better understanding of AIH in diverse racial and ethnic groups, emphasizing the need for tailored healthcare strategies.
This journal compares the effectiveness of Heplisav-B and standard hepatitis B vaccines as boosters for healthcare workers with low immunity to hepatitis B, measured by anti-HBs antibody levels. Results show that Heplisav-B offers a significantly higher seropositivity rate (99.4%) compared to the standard vaccine (92.7%).
This journal outlines best practices for engaging communities affected by chronic hepatitis B, emphasizing the importance of involving individuals with lived experiences in public health initiatives to improve diagnosis and treatment outcomes.